“We are excited to welcome Brunde to our board of directors. She brings decades of leadership experience in key areas critical to the growth of our business and vital to our future operations and strategy. Brunde’s expertise is especially valuable to Neurodon as an emerging company.” said Dr. Russell Dahl, Neurodon’s CEO, and founder.
Brunde graduated from Yale’s MBA program and became a partner in a family-controlled venture firm. The firm maintains several long-term investments and has funded several start-ups from their inception. The firm’s worldwide portfolio has interests in England, Germany, and China in nutraceuticals, software, technology, and, most recently, biopharma. Her network of individuals and companies has long standing relationships with individuals at the NIH, FDA, academic Institutions, as well as pharma and biotech VCs.